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Poor drugability problems are commonly seen in a class of chemical entities with poor solubility in water and oil, and
moreover, physicochemical instability of these compounds poses extra challenges in design of dosage forms. Such
problems contribute a significant high failure rate in new drug development. A hybrid nanoparicle-in-oil-in-water (N/O/W)
submicron emulsion was proposed for improved delivery of poorly soluble and unstable drugs (e.g., dihydroartemisinin
(DHA)). DHA is known for its potent antimalarial effect and antitumor activity. However, its insolubility and instability impose
big challenges for formulations, and so far, no injectable dosage forms are clinically available yet. Therefore, an injectable
DHA N/O/W system was developed. Unlike other widely-explored systems (e.g., liposomes, micelles, and emulsions), in
which low drug load and only short-term storage are often found, the hybrid submicron emulsion possesses three-fold
higher drug-loading capacity than the conventional O/W emulsion. Of note, it can be manufactured into a freeze-drying
form and can render its storage up to 6 months even in room temperature. The in vivo studies demonstrated that the PK
profiles were significantly improved, and this injectable system was effective in suppressing tumor growth. The strategy
provides a useful solution to effective delivery of such a class of drugs.
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Poor solubility of a chemical entity is a major obstacle
affecting its drugability [1]. It is estimated that more
than 40% of the new chemical entities generated in drug
discovery programs are poorly soluble [2]. With growing
interest in the role of modern pharmaceutics in early
stage of drug discovery and development, rationale de-
sign of drug delivery systems for poorly soluble drugs
has been widely explored, such as emulsions [3,4], solid
lipid nanoparticles [5,6], micelles, and liposomes [7,8].
Emulsions are one of the most commonly used drug car-
riers for poorly water-soluble drugs due to the unique
advantage in mass manufacturing, easy sterilization, and
excellent physicochemical stability. However, there still
remain two problems waiting to be solved, i.e., low drug-
loading capacity and quick drug release. Moreover, for* Correspondence: wqliang@zju.edu.cn; yzhuang@mail.shcnc.ac.cn
1Zhejiang University College of Pharmaceutical Sciences, 388 Yuhangtang
Road, Hangzhou 310058, China
2Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501
Hai-ke Road, Shanghai 201203, China
Full list of author information is available at the end of the article
© 2012 Wang et al.; licensee Springer. This is a
Attribution License (http://creativecommons.or
in any medium, provided the original work is pthe drugs that remain insoluble in both water and oil,
there is no satisfactory solution yet. As a case in point,
dihydroartemisinin (DHA), a potent antimalarial drug
[9,10], is poorly soluble and unstable, and its oral bioavail-
ability is low due to degradation in the gastrointestinal
tract and poor intestinal absorption. Moreover, because of
its unfavorable solubility property, no injectable dosage
form is clinically available yet, thus, severely limiting its use
in medical emergency in severe malaria. According to
WHO, an estimated 781,000 deaths from malaria in 2009,
and most victims are children under five [11]. Further-
more, DHA recently has been demonstrated for its extra-
ordinary antitumor activity and its promising development
into anticancer drug [12-14]. Therefore, to develop an in-
jectable drug delivery system for DHA is not only clinically
beneficial for these diseases, but also such exploration is
meaningful for rationale design of drug delivery for the
class of water/oil insoluble drugs.
Herein, we propose a novel hybrid system of the nano-
particle-in-oil-in-water (N/O/W) submicron emulsion.
Considering the oil compatibility, solid lipid nanoparticlesn Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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dispersed in oil as oily phase, and the oily phase was used to
dispersed in aqueous solution with homogenization for prep-
aration of the N/O/W submicron emulsion (Figure 1).
Materials and methods
Materials
Dihydroartemisinin (purity> 99%) was kindly provided by
Beijing Zhongyan Tongrentang Medicine R&D Co., Ltd.
(Beijing, China). Poloxamer 188 was purchased from
BASF Corporation (Ludwigshafen, Germany), cholesterol
from Pharmacia Biothech (Piscataway, NJ, USA), and soya
phosphatidylcholine from Lipoid GmbH (Ludwighafen,
Germany). Mannitol, sucrose, and glyceryl monostearate
were purchased from Sinopharm Chemical Reagent Co.,
Ltd. (Shanghai, China). Hepatic H22 cell line was kindly
provided by Zhejiang University of Traditional Chinese
Medicine. All other chemicals were of analytical grade.
Preparation of DHA N/O/W emulsion
DHA (150 mg) and lecithin (900 mg) were dissolved in 30-
ml alcohol and then mixed with soybean oil (5,000 mg) and
glyceryl monostearate (150 mg). The mixture was used as
oily phase and warmed up to 60°C and then dropwise added
to the aqueous phase containing glycerol (1,100 mg) and
poloxamer 188 (900 mg) with agitation at high speed and
temperature (8,000 to 10,000 rpm and 60°C). After adjusting
the pH from 6 to 7, the primary emulsion was homogenized
by microfluid technology at a pressure of 200 to 1,000 bar (8
to 10 cycles) to obtain the DHA N/O/W emulsion with
DHA concentration about 3.0 mg/ml. In order to maintain
DHA stability, the freeze-dried emulsion was prepared with
a complex of sucrose and mannitol (4:1) as lyoprotectant.Figure 1 Schematic illustration of the preparation of
nanoparticle-in-oil-in-water (N/O/W) submicron emulsion.Meanwhile, the DHA O/W emulsion was prepared as
follows. DHA (49 mg) and lecithin (1,000 mg) were dis-
solved in alcohol and attached to a rotary evaporator to
remove the organic solvent. Soybean oil (5,000 mg) was
then added to dissolve the dried film as oil phase. Aque-
ous phase contained glycerol (1,100 mg); poloxamer, 188
(1,000 mg). The DHA O/W emulsion was prepared as
described above.
Characterization of the DHA N/O/W emulsion
Size and zeta potential of the DHA N/O/W emulsion
were determined by laser scattering technique using
Malvern ZS90 (Malvern Instruments Ltd., Malvern,
Worcestershire, UK) after appropriate dilution with
double distilled water.
The primary N/O/W emulsion with a size of about 10
μm (before microfluid process), through light micros-
copy (MPS-30, Leica Microsystems, Wetzlar, Hesse,
Germany), was employed to observe the encapsulation
of particles in O/W emulsion. Furthermore, morphology
of the mid-product of DHA N/O/W emulsion (about 1
μm) was studied with transmission electron microscopy
(TEM) (JEM-1200EX, JEOL Ltd., Akishima, Tokyo,
Japan). The sample for TEM was dropped onto a 400-
mesh copper grid coated with carbon film. The sample
was dried in air before TEM observation. The sample for
freeze-fracture transmission electron microscopy (FF-
TEM) was prepared as follows. A droplet of microemul-
sion was sandwiched between two copper electron mi-
croscopy grids, snapfrozen by immersion in liquid
ethane, and then loaded into a double-replica device and
immersed in liquid nitrogen (−196°C). The double rep-
lica device was mounted on the rotary sample stage of a
Balzers BAF-400D freeze etch device (Balzers AG, Bal-
zers, Liechtenstein) cooled to −110°C. Fracturing was
carried out at a vacuum of 3 × 10−3 mbar. The fractured
surfaces were shadowed with platinum (45°) and carbon
(90°). The replicas were then washed in chloroform,
methanol, and finally, distilled water. Dried replicas were
examined with TEM operating at an accelerating voltage
of 80 kV.
Drug loading capacity
The DHA N/O/W emulsion was dissolved in methanol
and then injected to the high-performance liquid chro-
matography (HPLC) system. Chromatographic separ-
ation was achieved using a C18 column (150 × 4.6 mm, 5
μm, Agilent Technologies, Palo Alto, CA, USA) with
column temperature at 40°C. The mobile phase con-
sisted of 40:60 double-distilled water containing 0.1%
acetic acid (Millipore Corporation, Milford, MA, USA)/
acetonitrile (HPLC grade, Merck & Co., Inc., White-
house Station, NJ, USA). The flow rate was set to 1.0
ml/min, and UV detection wavelength was 210 nm.
Figure 2 The changes of DHA content and size of the
reconstituted N/O/W emulsion at different storage periods.
Figure 3 Light micrographs (A), TEM micrographs (B) and FF-TEM mic
emulsion (right).
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The experimental protocols were approved by the Animal
Ethics Review Committee of Zhejiang University. The
male rabbits (2.0 ± 0.2 kg) were divided into three groups
(6 per group). DHA solution, DHA O/W emulsion or
DHA N/O/W emulsion was injected via ear vein at a dose
of 6.2 mg/kg. Blood samples were collected from the mar-
ginal vein on another ear before administration and at pre-
determined time points after intravenous administration.
Plasma sample (100 μl) was spiked with 10 μl of the IS so-
lution (artemisinin, 1 μg/ml), and the mixture was vor-
texed for 10 s. The sample was extracted with 2-ml ethyl
acetate, vortexed for 3 min, and centrifuged for 15 min at
3,500 rpm. The upper layer was transferred into another
test tube and evaporated to dryness under a gentle stream
of N2 gas at 37°C. The residue was reconstituted in 100 μl
of methanol/water (60:40). The concentration of DHA inrographs (C) of DHA N/O/W emulsion (left) and DHA O/W
Figure 4 Plasma concentration-versus-time profiles of DHA
after intravenous administration of 6.2 mg/kg DHA N/O/W
emulsion to rabbits, DHA solution and DHA O/W emulsion as
controls.
Wang et al. Nanoscale Research Letters 2012, 7:219 Page 4 of 7
http://www.nanoscalereslett.com/content/7/1/219plasma samples was determined by LC-MS method (ESI,
positive mode, Agilent 1100 LC-MSD, Agilent Technolo-
gies, Palo Alto, CA, USA). Pharmacokinetic analysis was
conducted using Kinetica Software (Version 4.4, Thermo
Electron Corporation, Waltham, MA, USA).In vivo antitumor efficacy of DHA N/O/W emulsion
Hepatic H22 tumor cells (5 to 6 × 10
6 cells per mouse)
were inoculated subcutaneously to the Institute for Can-
cer Research (ICR) mice (6 to 8 weeks, 22 to 26 g) at the
right axilla. Tumors were measured by a vernier caliper,
and its volume (V) was calculated as follows:
V ¼ d2  D=2;
where d and D are the shortest and the longest diameter
of the tumor in mm, repectively.
When the tumor grew to a mean size of approxi-
mately 300 mm3, mice were treated intravenously (i.v.)
with DHA solution, DHA O/W emulsion, or N/O/W
emulsion.Table 1 Pharmacokinetic parameters of DHA
Parameters DHA N/O/W emulsion
t1/2α (min) 9.40 ± 0.28*
,**
t1/2β (min) 160.91 ± 47.21*
,**
Cl (mlmin−1kg) 0.0023 ± 0.0002*,**
AUC (minngml−1) 219,759.00 ± 14,782.77*,**
MRT (min) 97.65 ± 20.27*,**
Parameters of DHA after intravenous administration of DHA N/O/W emulsion to rab
expressed as mean ± S.D. (n = 6), *P < 0.01 vs. DHA solution, **P < 0.01 vs. DHA OHemolysis test and vascular irritation test
Blood sample was collected from New Zealand white
rabbit (2.5 kg) ear vein. A 10-ml aliquot of defibrinated
blood and 10 ml of saline were mixed and centrifuged.
The supernatant was discarded, and the wash step was
repeated three times until no red color was observed in
the supernatant. Erythrocytes were diluted with saline to
2% (v/v). The DHA N/O/W emulsion at varying concen-
trations was mixed with 2% erythrocyte solution in equal
volume. The morphology of the erythrocytes was
observed under the microscope, and the color change of
the solution was monitored with spectrophotometry
(λ= 414 nm) for hemolysis evaluation. Hemolysis effect
was calculated as follows:




where Asample is the absorbance of the tested sample;
Anegative, the absorbance of the negative control (i.e.,
mixture of equal volumes of 2% erythrocytes and saline);
and Apositive, the absorbance of the positive control (i.e.,
mixture of equal volumes of 2% erythrocytes and dis-
tilled water).
For vascular irritation test, DHA N/O/W emulsion
with a DHA dose of 6.2 mg/kg was injected to the mar-
ginal ear vein once per day for 7 days. At the eighth day,
the rabbits were killed by aortic bleeding under pento-
barbital anesthesia. The vascular irritation was investi-
gated by histological examination of the injection site.
Statistical analysis
Each experiment was performed in triplicate, and the
values were expressed as mean ± S.D. Statistical analysis
was performed using Student's t test. Significant differ-
ences are demonstrated by symbols (*, **).
Results and discussion
Preparation and characterization of DHA N/O/W emulsion
DHA N/O/W emulsion was prepared by a modified
solvent evaporation and membrane emulsification
method. The drug-loading capacity was improved by the
DHA N/O/W emulsion, in which DHA concentrationDHA O/W emulsion DHA solution
3.97 ± 0.34 3.10 ± 0.09
73.31 ± 1.61* 20.20 ± 6.56
0.0038 ± 0.0002* 0.0069 ± 0.0013
131,564.5 ± 8,396.89* 73,025.35 ± 14,149.00
32.22 ± 4.03* 9.40 ± 2.44
bits, DHA solution, and DHA O/W emulsion as controls. The results are
/W emulsion.
Figure 5 Mean relative tumor volume in DHA N/O/W emulsion
(45 mg/kg), DHA N/O/W emulsion (11.25 mg/kg), DHA solution
(11.25 mg/kg), and N.S. control. (n = 10).








13.3 10.0 6.7 3.3
Hemolytic degree (%) 3.2 1.5 1.6 1.5 0 100
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DHA O/W emulsion (0.98 mg/ml).
The freeze-dried DHA N/O/W emulsion was able to
reconstitute in distilled water within 1 min. The average
particle size and zeta potential were 175 nm and −48.1
mV. The storage stabilities of DHA N/O/W emulsion
indicated that DHA N/O/W emulsion was stable at 4°C
for 1 month. The stability was further improved in
freeze-dry form, and the reconstituted emulsion showed
merely slight changes in the average particle size and
content of DHA at 25°C up to 6 months (Figure 2).
The representative light micrographs of the DHA N/
O/W and DHA O/W emulsions are presented in Fig-
ure 3A. Particles were observed in the oil droplets of pri-
mary N/O/W emulsion, clearly showing the successful
encapsulation of NP in oil droplets (magnification,
×400). As a control, no particles were seen in primary
O/W emulsion. Such NP encapsulation in N/O/W
emulsion (1 μm) was also found in TEM micrographs
(Figure 3B). FF-TEM is a powerful tool to provide a dir-
ect image of the inside structures of nanomaterials and
their morphology in a liquid sample, includingTable 2 In vivo anti-tumor effects of DHA and DHA N/O/








NS control - 21.9 ± 1.3/27.8 ± 2.2 1.4 ± 0.4 -
DHA solution 11.25 21.2 ± 1.2/25.3 ± 1.7 1.1 ± 0.3 21.5*
DHA N/O/W
(low dose)
11.25 22.3 ± 0.9/28.6 ± 2.3 1.1 ± 0.2 23.0*
DHA N/O/W
(high dose)
45.00 21.7 ± 1.1/26.3 ± 3.8 0.7 ± 0.2 51.8**
Note: *P< 0.05 and **P< 0.01 vs. N.S. control.
#P< 0.05 vs. DHA solution or low-dose group.emulsions [15] and nanoparticles [16]. Thus, FF-TEM
was used to observe the internal structure of DHA N/O/
W emulsion (Figure 3C). However, with the decrease in
particle size (nanoscale), the difference between DHA
N/O/W and DHA O/W emulsions becomes less appar-
ent. It primarily contributed to the fact that the imaging
resolution is not high enough to distinguish the internal
cores (nanoparticulate core and nanodroplet oil core)
under the freeze-fracture condition. Furthermore, the
shell structure of the N/O/W becomes thinner with the
decreasing particle size, and thus, the double layer of the
shell is less apparent. However, a minor distinction can
be seen that ‘wrinkles’ existed in the oil droplets of N/
O/W submicron emulsion while not in O/W emulsion.
Pharmacokinetics study
The plasma concentration-versus-time profiles are
shown in Figure 4. The half-life of DHA was signifi-
cantly prolonged in the group treated with DHA N/O/
W emulsion compared with the group of the DHA O/W
emulsion or the DHA solution. The pharmacokinetic
parameters are listed in Table 1. In the animals treated
with DHA solution, the blood DHA was rapidly cleared
and hardly detected after 0.75 h, with a t1/2β of 20 min.
However, a very significant improvement was seen in the
group of DHA N/O/W emulsion, showing eight-fold in-
crease in t1/2β (160 min). As a result, the area under the
plasma concentration-versus-time curve (AUC) of DHA
N/O/W emulsion group displayed nearly three times
higher than that of the DHA solution group and 1.7
times higher than that of the DHA O/W emulsion. It
demonstrated the advantages of improved PK profiles
and the potential superior treatment outcomes of DHA
N/O/W emulsion.
In vivo antitumor efficacy of DHA N/O/W emulsion
Tumor-bearing mice transplanted with murine hepatic
H22 cells were used to investigate the antitumor effect of
DHA. During the treatment regime, tumor volume was
monitored at a daily basis. Figure 5 shows the variation
of tumor volume after H22 bearing mice were treated by
i.v. injection of saline, DHA solution, and DHA N/O/W
emulsion, respectively. The group treated with DHA N/
O/W emulsion (45 mg/kg eq) displayed the strongest
tumor growth inhibition and smallest tumor volumes (P
< 0.01). In contrast, severe side effects (e.g., animal
death) were seen in the group treated with DHA
Figure 6 Histopathological sections of rabbit ears after intravenous administration of (A) DHA N/O/W emulsion and (B) Sodium
chloride injection.
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dose. The tumor inhibition rate of DHA N/O/W emul-
sion was 51.8% (Table 2). Thus, it demonstrated the
enhanced antitumor efficacy and the reduced toxicity of
DHA with the N/O/W emulsion formulation.
Elementary safety assay
Hemolysis and vascular irritation evaluations are import-
ant for parenteral preparations before in vivo investiga-
tion because vessels and erythrocytes are the initial parts
of the body that encounter and interact with i.v. injected
preparations. Thus, the tests provide preliminary safety
evaluation for DHA N/O/W emulsion. The DHA N/O/
W emulsion displayed excellent biocompatibility. There
were neither broken nor agglutinated erythrocytes
observed under the microscope when exposed to the
DHA N/O/W emulsion in the tested concentration
range, and all samples showed less than 5% of hemolytic
degree (Table 3).
The vascular irritation test also demonstrated the
safety of the DHA N/O/W emulsion in rabbits as shown
in Figure 6. There was no swelling, thrombus, degener-
ation, or inflammatory cell infiltration observed in the
histological examination after i.v. administration of the
DHA N/O/W emulsion at the dose of 2.5 mg/kg. Our
results indicated the biocompatibility of the injectable
DHA N/O/W emulsion.
Conclusion
A novel N/O/W submicron emulsion with high drug-
loading capacity was prepared for intravenous adminis-
tration of poorly soluble and unstable drugs. Our strat-
egy is able to not only enhance the drug solubility in theemulsion but also improve its storage stability by freeze-
drying. The pharmacokinetics of N/O/W emulsion are
characterized by the significantly prolonged half-life and
slow plasma clearance compared with conventional O/
W emulsion and DHA solution. Presumably due to the
improved PK profiles, the toxic effect of DHA was
greatly reduced. Furthermore, the antitumor efficacy was
demonstrated in vivo studies using a hepatic H22 tumor
transplanted mouse model. More importantly, with the
advantages of the high drug-loading capacity, easy
manufacturing process, and excellent biocompatibility,
the N/O/W emulsion provides a promising solution for
developing injectable drug delivery systems for a class of
drugs of poor water solubility and stability.
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